Wein Matthew sold $725 of MGX
Wein Matthew (See Remarks) sold 558 shares of Metagenomi Therapeutics, Inc. (MGX) at $1.30 on 2026-06-05.
How this was made
The 30-second read
Why it matters
Discloses an officer’s open-market sale of 558 shares at $1.2990/share; no additional company developments are included.
Market read
Primarily a compliance disclosure; limited trading edge absent other contemporaneous catalysts.
What to watch
Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; the filing provides no rationale or linkage to company events.
Background
The article reports an SEC Form 4 insider transaction for Metagenomi Therapeutics, Inc.
Ticker impact
Metagenomi Therapeutics insider Form 4 shows officer Matthew Wein sold 558 shares in an open-market transaction on 2026-06-05.
Minimal near-term impact; any effect is likely noise unless paired with other negative catalysts.
The article is a Form 4 insider transaction with modest dollar value ($724.84) and no 10b5-1 plan, but insider sales alone are typically low-signal without corroborating company-specific news.
Market effects
No clear sector read-through from a single small insider sale.
None indicated.
None indicated.
Counterpoint
The absence of a 10b5-1 plan could be interpreted as discretionary selling, but the transaction size is too small to be a strong fundamental signal.
Key entities
- issuerMetagenomi Therapeutics, Inc.
Company whose insider transaction is disclosed on SEC Form 4 (MGX).
- insiderWein Matthew
Officer who sold 558 shares on 2026-06-05.
